CDMO (CDMO) Stock Analysis
DELISTED 2025
What happened to CDMO (CDMO) stock?
CDMO (CDMO) no longer trades on public markets. It was delisted in February 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CDMO (CDMO) trades at $12.49. Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO) focused on biopharmaceutical drug substances derived from mammalian cell culture. Market cap: $799M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for CDMO: CDMO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CDMO against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
CDMO: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →CDMO (CDMO) Healthcare & Pipeline Overview
Avid Bioservices, Inc. (CDMO) is a contract development and manufacturing organization specializing in biopharmaceutical drug substances. The company offers comprehensive services, including process development and commercial manufacturing, primarily serving biotechnology and biopharmaceutical clients, positioning it as a key partner in the outsourced biomanufacturing space.
What Is the Investment Thesis for CDMO?
Avid Bioservices presents a compelling investment case within the CDMO sector, driven by the increasing demand for outsourced biomanufacturing services. The company's focus on mammalian cell culture-derived drug substances positions it favorably in a market where monoclonal antibodies and recombinant proteins are significant growth drivers. While the company currently has a negative profit margin of -100.6% and a gross margin of 5.2%, strategic investments in capacity expansion and operational efficiencies could improve profitability. Key catalysts include securing new manufacturing contracts and successful regulatory approvals for client products. Potential risks include competition from larger CDMOs and fluctuations in demand for biopharmaceutical manufacturing services. Investors should monitor the company's ability to scale operations effectively and maintain high-quality standards to capitalize on industry growth.
Based on FMP financials and quantitative analysis
CDMO Key Highlights
Avid Bioservices operates as a contract development and manufacturing organization (CDMO), capitalizing on the growing trend of biopharmaceutical companies outsourcing manufacturing.
- The company specializes in mammalian cell culture, a key technology for producing monoclonal antibodies and recombinant proteins.
- Avid Bioservices offers a comprehensive suite of services, from process development to commercial manufacturing, providing a one-stop solution for its clients.
- The company serves both biotechnology and biopharmaceutical industries, diversifying its revenue streams.
- Headquartered in Tustin, California, Avid Bioservices is strategically located in a region with a strong presence of biotechnology companies.
Who Are CDMO's Competitors?
CDMO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GNFTF Genfit S.A. | $16.28 | -1.33% | $816M | 73 |
| RIGL Rigel Pharmaceuticals, Inc. | $45.09 | -3.97% | $834M | 84 |
| TBPH Theravance Biopharma, Inc. | $16.95 | -0.24% | $878M | 95 |
| ZVRA Zevra Therapeutics, Inc. | $11.89 | -1.98% | $703M | 93 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| ABUS Arbutus Biopharma Corporation | $4.77 | -4.22% | $942M | 83 |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
| CRMD CorMedix Inc. | $8.33 | -2.19% | $654M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CDMO's Key Strengths?
Specialized expertise in mammalian cell culture.
- Comprehensive service offerings from process development to commercial manufacturing.
- Strong relationships with biotechnology and biopharmaceutical clients.
- Proven track record of CGMP compliance.
What Are CDMO's Weaknesses?
Negative profit margin.
- Reliance on a limited number of clients.
- Smaller scale compared to larger CDMOs.
- High capital expenditure requirements for capacity expansion.
What Could Drive CDMO Stock Higher?
Securing new manufacturing contracts with biotechnology and biopharmaceutical companies.
- Successful regulatory approvals for client products manufactured by Avid Bioservices.
- Expansion of manufacturing capacity to meet increasing demand.
- Strategic partnerships and acquisitions to expand service offerings and geographic reach.
What Are the Key Risks for CDMO?
Financial-distress signal — its Altman Z-Score of -0.58 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger CDMOs with greater resources and capabilities.
- Fluctuations in demand for biopharmaceutical manufacturing services.
- Regulatory changes and compliance requirements that could increase costs.
- Reliance on a limited number of clients, posing a risk to revenue stability.
- Negative profit margin, requiring improvements in operational efficiency and cost management.
What Are the Growth Opportunities for CDMO?
- Expansion of Manufacturing Capacity: Avid Bioservices can capitalize on the increasing demand for biomanufacturing by expanding its production capacity. Investing in new facilities and equipment will enable the company to handle larger contracts and serve more clients. The biopharmaceutical CDMO market is expected to grow significantly, presenting a substantial opportunity for Avid Bioservices to increase its market share. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Forming strategic alliances with biotechnology and pharmaceutical companies can provide Avid Bioservices with access to new technologies, markets, and clients. Acquisitions of smaller CDMOs with complementary capabilities can further expand the company's service offerings and geographic reach. The CDMO market is consolidating, making strategic partnerships and acquisitions a viable growth strategy. Timeline: Ongoing.
- Focus on High-Growth Therapeutic Areas: Targeting specific therapeutic areas with high growth potential, such as oncology and immunology, can drive revenue growth for Avid Bioservices. Developing specialized expertise and manufacturing capabilities in these areas will attract clients developing innovative therapies. The oncology and immunology markets are experiencing rapid growth, fueled by advancements in personalized medicine and targeted therapies. Timeline: Ongoing.
- Enhancement of Process Development Capabilities: Investing in advanced process development technologies and expertise can improve manufacturing efficiency, reduce costs, and accelerate timelines for clients. Offering innovative process development solutions will differentiate Avid Bioservices from its competitors and attract clients seeking cutting-edge technologies. The biopharmaceutical industry is constantly evolving, requiring CDMOs to stay ahead of the curve in process development. Timeline: Ongoing.
- Geographic Expansion: Expanding operations to new geographic regions, such as Europe and Asia, can provide access to new markets and clients. Establishing manufacturing facilities or partnerships in these regions will enable Avid Bioservices to serve a global client base. The biopharmaceutical industry is increasingly global, with significant growth opportunities in emerging markets. Timeline: Ongoing.
What Are CDMO's Competitive Advantages?
- Specialized Expertise: Deep expertise in mammalian cell culture and biopharmaceutical manufacturing.
- Long-Term Relationships: Strong relationships with biotechnology and biopharmaceutical clients.
- Scalable Manufacturing: Ability to scale manufacturing from clinical to commercial production.
- Regulatory Compliance: Proven track record of CGMP compliance and regulatory approvals.
What Does CDMO Do?
Avid Bioservices, Inc., established in 1981 and headquartered in Tustin, California, operates as a contract development and manufacturing organization (CDMO) focused on providing comprehensive services for biopharmaceutical drug substances derived from mammalian cell culture. Originally incorporated as Peregrine Pharmaceuticals, Inc., the company rebranded as Avid Bioservices in January 2018 to better reflect its core business. Avid Bioservices offers a range of services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company produces monoclonal antibodies and recombinant proteins, catering to the biotechnology and biopharmaceutical industries. Their process development services encompass upstream and downstream development and optimization, analytical methods development, testing, and characterization. Avid Bioservices plays a crucial role in supporting its clients from early-stage development through commercialization, offering scalable manufacturing solutions and expertise in complex biologics.
What Products and Services Does CDMO Offer?
- Provides contract development and manufacturing services to biotechnology and biopharmaceutical companies.
- Specializes in manufacturing biopharmaceutical drug substances derived from mammalian cell culture.
- Produces monoclonal antibodies and recombinant proteins.
- Offers CGMP clinical and commercial drug substance manufacturing.
- Provides bulk packaging, release and stability testing, and regulatory submission support.
- Offers upstream and downstream development and optimization services.
- Provides analytical methods development, testing, and characterization services.
How Does CDMO Make Money?
- Generates revenue by providing contract manufacturing services to biotechnology and biopharmaceutical companies.
- Charges fees for process development, clinical manufacturing, and commercial manufacturing services.
- Revenue is based on the scope and complexity of the manufacturing projects.
- Forms long-term partnerships with clients to provide ongoing manufacturing support.
What Industry Does CDMO Operate In?
Avid Bioservices operates within the rapidly expanding biopharmaceutical CDMO market. The industry is driven by the increasing complexity of biologics, the rising cost of in-house manufacturing, and the growing demand for specialized expertise. The global CDMO market is projected to reach significant growth in the coming years, fueled by advancements in biopharmaceutical research and development. Competition is intense, with several large players and smaller niche providers. Avid Bioservices differentiates itself through its focus on mammalian cell culture and its comprehensive service offerings, positioning it to capture a share of this expanding market.
Who Are CDMO's Key Customers?
- Biotechnology companies developing novel therapies.
- Biopharmaceutical companies seeking to outsource manufacturing.
- Companies requiring CGMP manufacturing for clinical trials.
- Companies requiring commercial-scale manufacturing for approved products.
How CDMO Is Valued
CDMO carries a market capitalization of $799M, placing it in the small-cap category.
Company Profile
CDMO operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tustin, US. The company is led by CEO Nicholas Stewart Green MBA. CDMO has traded publicly since 1994.
Key Financial Metrics
Return on assets is -41.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
CDMO's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.58 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project CDMO revenue of about $224.9M for fiscal 2027, with EPS near $0.18.
CDMO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized expertise in mammalian cell culture.
- Comprehensive service offerings from process development to commercial manufacturing.
- Strong relationships with biotechnology and biopharmaceutical clients.
- Proven track record of CGMP compliance.
Bear Case
- Negative profit margin.
- Reliance on a limited number of clients.
- Smaller scale compared to larger CDMOs.
- High capital expenditure requirements for capacity expansion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CDMO Latest News
-
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
gurufocus.com · Jun 22, 2026
-
Stocks That Hit 52-Week Highs On Friday
· Dec 13, 2019
Leadership: Nicholas Stewart Green MBA
CEO
Nicholas Stewart Green is the Chief Executive Officer of Avid Bioservices, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on operations, manufacturing, and business development. He holds an MBA degree, providing him with a strong foundation in business strategy and financial management. Prior to joining Avid Bioservices, Green held leadership positions at various biopharmaceutical companies, where he was responsible for overseeing manufacturing operations and driving growth initiatives. His experience includes managing large teams and implementing operational improvements.
Track Record: Under Nicholas Green's leadership, Avid Bioservices has focused on expanding its manufacturing capacity and capabilities to meet the growing demand for outsourced biomanufacturing services. He has overseen strategic investments in new facilities and equipment, as well as initiatives to improve operational efficiency and quality. Key milestones under his tenure include securing new manufacturing contracts and expanding the company's client base.
What Investors Ask About CDMO (CDMO) — Healthcare
What happened to CDMO (CDMO) stock?
CDMO (CDMO) no longer trades on public markets. It was delisted in February 2025. The figures below are historical and are not a current quote.
Can I still buy CDMO shares?
No. CDMO stopped trading on public markets in February 2025, so the shares are not available through a broker. Anything you see quoted for CDMO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CDMO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to CDMO. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Avid Bioservices, Inc. do?
Avid Bioservices, Inc. operates as a contract development and manufacturing organization (CDMO), providing services to biotechnology and biopharmaceutical companies. They specialize in manufacturing biopharmaceutical drug substances derived from mammalian cell culture, including monoclonal antibodies and recombinant proteins.
What do analysts say about CDMO stock?
Analyst coverage of Avid Bioservices (CDMO) typically focuses on the company's growth prospects within the expanding CDMO market. Key valuation metrics include revenue growth, gross margin, and earnings per share. Analysts consider the company's ability to secure new manufacturing contracts, expand its capacity, and maintain high-quality standards as important drivers of future performance.
What are the main risks for CDMO?
Avid Bioservices faces several risks inherent to the CDMO industry. Competition from larger, more established CDMOs with greater resources poses a significant threat. Fluctuations in demand for biopharmaceutical manufacturing services can impact revenue stability. Regulatory changes and compliance requirements can increase costs and complexity.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent available data.